Three serum tumor markers (TMs)-carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA125)-may play a role in preoperative and postoperative risk estimation and decision-making in patients undergoing CRS-HIPEC.<h4>Objective</h4>To evaluate the association of preoperative and postoperative serum TM levels with outcomes in patients with AA or goblet cell adenocarcinoma (GCA) undergoing CRS-HIPEC.<h4>Design, setting, and participants</h4>This retrospective cohort study was conducted in a single quaternary referral cancer center. This evidence concerns the gene MUC16 and goblet cell carcinoma.